As BRAF-inhibitors become standard treatment for many metastatic melanoma patients, research has begun to elucidate their impact on the tumor immune landscape. Here, we highlight our recent studies demonstrating the ability of melanoma cell-intrinsic BRAF-inhibition to selectively reduce intratumoral immunosuppressive cell populations and enhance antitumor CD8 T-cell immunity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404921 | PMC |
| http://dx.doi.org/10.4161/2162402X.2014.988039 | DOI Listing |
Publication Analysis
Top Keywords
tumor immune
8
braf-inhibition tumor
4
immune suppression
4
suppression braf-inhibitors
4
braf-inhibitors standard
4
standard treatment
4
treatment metastatic
4
metastatic melanoma
4
melanoma patients
4
patients begun
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!